A Meta Study of Omega-3 (EPA / DHA), in Five Population-Based Categories, Reveals That the Slow Rate of Conversion is Genetic, Says Nutri-Med Logic Corp.
Nutri-Med Logic Corp. says that the Meta analysis of 8,866 subjects, the findings of genetic variations relating to the conversion rate of Alpha Linolenic to EPA and/or DHA of Omega-3, is a form of suggesting, in our opinion, that EPA and DHA of Omega-3 from dietary supplements might be a more suitable from than the type of Omega-3 found in conventional foods.
Miami, Florida (PRWEB) August 24, 2011
Nutri-Med Logic Corp: Which one is more efficient, Omega-3 from dietary supplements or conventional food?
The results of the new Meta Analysis published by the Public Library of Science (PLoS) Genetics has found lower conversation rate from plant Omega-3 (ALA) to its final derivatives of EPA and DHA, in five population-based categories.
The term Omega-3 refers to a chain of polyunsaturated fatty acids that starts with Alpha-Linolenic Acid (ALA) and ends in Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA). EPA and DHA are the two most beneficial and the most studied end-results of ALA for the body.
EPA and DHA of Omega-3 can be attained directly from dietary Omega-3 supplements or through metabolic conversion from ALA, which is mostly found in seeds and plants.
In the human body, ALA gets converted EPA and DHA through certain enzymes (proteins) called Fatty Acid Desaturases (FADS), for the sole purpose of being incorporated into Phospholipids, which is the principal components of cellular immune reaction to antigens (substances foreign to the body).
According to this Meta Study, higher levels of Omega-3 in the phospholipids have been associated with lower risk of multiple diseases such as sudden cardiac death, fatal coronary heart disease, non-fatal myocardial infarction, heart failure, thickening of the carotid arteries, metabolic syndrome, breast cancer, chronic obstructive pulmonary disease, depression and dementia (1-12).
The role of EPA and DHA of Omega -3 vs. ALA, in Metabolic Syndrome was outlined in our Release of August 14, 2011.
This new Meta Study not only re-affirms our Release of 8/14/2011 but also sheds new light to other beneficial areas for a diet rich in Omega-3.
The study found that the higher ratio of ALA in the body corresponded to lower levels of EPA and DHA, suggesting a lower rate (inefficiency) in conversion of ALA to EPA / DHA. While the study included 8,866 subjects of European ancestry but samples of African, Chinese, and Hispanic ancestry, associations were found to be similar with FADS. FADS convert ALA to EPA and DHA
In conclusion, Nutri-Med Logic Corp. agrees with the finding of this Meta Analysis but believes that the result of future studies should also contain a language recommending direct dietary supplementation of EPA and DHA of Omega-3.
Nutri-Med Logic Corp is a producer of dietary supplements, including a Concentrated and Balanced Omega-3: having the same concentration of EPA and DHA, 50% Ã¢“ 50%.
DHA of Omega-3 offers beneficial properties mainly for the brain, nervous system and EPA of Omega-3 offers beneficial properties in cardiovascular system.
Nutri-Med LogicÃ¢s products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and, also, packaged in pharmaceutical facilities.
It must be noted that the studies, sources or statements, above and below, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of Omega-3 dietary supplementation; nor equate its supplementation to prevention, treatment or cure.
1- Jama 274: 1363Ã¢“1367
2- Circulation 114: 209Ã¢“215.
3- Am J Clin Nutr 88: 216Ã¢“223
4- Am Heart J 156: 965Ã¢“974
5- Am J Clin Nutr 92: 186Ã¢“193
6- Am J Clin Nutr 84: 442Ã¢“448
7- Am J Clin Nutr 85: 1090Ã¢“1097
8- Am J Respir Crit Care Med 159: 1780Ã¢“1785
9- Am J Clin Nutr 78: 40Ã¢“46
10- Am J Clin Nutr 87: 1156Ã¢“1162
11- Am J Clin Nutr 88: 714Ã¢“721
12- Arch Neurol 63: 1545Ã¢“1550
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/8/prweb8742385.htm